Company Overview

Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates in the musculoskeletal healthcare business in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company designs, manufactures, and markets orthopaedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; spine products comprising medical devices and surgical instruments; and face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest toss facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers dental products that include dental reconstructive implants, and dental prosthetic and regenerative products, as well as robotic, surgical and bone cement products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, oral surgeons, dentists, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.

  • Name

    Zimmer Biomet Holdings, Inc.

  • CEO

    Mr. Ivan Tornos

  • Website

    www.zimmerbiomet.com

  • Sector

    Health Care Equipment and Supplies

  • Year Founded

    1927

Profile

  • Market Cap

    $21.28B

  • EV

    $26.9B

  • Shares Out

    203.65M

  • Revenue

    $7,524.8M

  • Employees

    18,000

Margins

  • Gross

    71.79%

  • EBITDA

    33.5%

  • Operating

    20.68%

  • Pre-Tax

    13.57%

  • Net

    13.25%

  • FCF

    13%

Returns (5Yr Avg)

  • ROA

    2.04%

  • ROTA

    7.56%

  • ROE

    3.78%

  • ROCE

    6.29%

  • ROIC

    5.6%

Valuation (TTM)

  • P/E

  • P/B

  • EV/Sales

  • EV/EBITDA

  • P/FCF

  • EV/Gross Profit

Valuation (NTM)

  • Price Target

    $126.81

  • P/E

  • PEG

  • EV/Sales

  • EV/EBITDA

  • P/FCF

Financial Health

  • Cash

    $420.1M

  • Net Debt

    $5,614.5M

  • Debt/Equity

    0.47

  • EBIT/Interest

    7.66

Growth (CAGR)

  • Rev 3Yr

    0.65%

  • Rev 5Yr

    -0.9%

  • Rev 10Yr

    4.91%

  • Dil EPS 3Yr

    2.99%

  • Dil EPS 5Yr

    22.19%

  • Dil EPS 10Yr

    0.53%

  • Rev Fwd 2Yr

    4.59%

  • EBITDA Fwd 2Yr

    6.28%

  • EPS Fwd 2Yr

    6.99%

  • EPS LT Growth Est

    7.09%

Dividends

  • Yield

  • Payout

    19.92%

  • DPS

    $0.96

  • DPS Growth 3Yr

  • DPS Growth 5Yr

  • DPS Growth 10Yr

    1.34%

  • DPS Growth Fwd 2Yr

    0.67%

NYSE:ZBH